AU2022305377A1 - Antibody binding to clostridium difficile - Google Patents

Antibody binding to clostridium difficile Download PDF

Info

Publication number
AU2022305377A1
AU2022305377A1 AU2022305377A AU2022305377A AU2022305377A1 AU 2022305377 A1 AU2022305377 A1 AU 2022305377A1 AU 2022305377 A AU2022305377 A AU 2022305377A AU 2022305377 A AU2022305377 A AU 2022305377A AU 2022305377 A1 AU2022305377 A1 AU 2022305377A1
Authority
AU
Australia
Prior art keywords
ser
amino acid
acid sequence
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022305377A
Other languages
English (en)
Inventor
Naoshi Dohmae
Toshio Hakoshima
Tomoyuki Mori
Reiko Shinkura
Ryutaro TAMANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nara Institute of Science and Technology NUC
University of Tokyo NUC
Original Assignee
Nara Institute of Science and Technology NUC
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nara Institute of Science and Technology NUC, University of Tokyo NUC filed Critical Nara Institute of Science and Technology NUC
Publication of AU2022305377A1 publication Critical patent/AU2022305377A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022305377A 2021-07-01 2022-06-30 Antibody binding to clostridium difficile Pending AU2022305377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-110421 2021-07-01
JP2021110421 2021-07-01
PCT/JP2022/026277 WO2023277142A1 (ja) 2021-07-01 2022-06-30 クロストリジウム・ディフィシル菌に結合する抗体

Publications (1)

Publication Number Publication Date
AU2022305377A1 true AU2022305377A1 (en) 2024-02-15

Family

ID=84692781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022305377A Pending AU2022305377A1 (en) 2021-07-01 2022-06-30 Antibody binding to clostridium difficile

Country Status (9)

Country Link
US (1) US20250188157A1 (https=)
EP (1) EP4365293A4 (https=)
JP (3) JP7425452B2 (https=)
KR (1) KR20240026999A (https=)
CN (1) CN117716035A (https=)
AU (1) AU2022305377A1 (https=)
CA (1) CA3224497A1 (https=)
TW (1) TW202317611A (https=)
WO (1) WO2023277142A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440928A (zh) 2023-03-03 2024-10-16 國立大學法人東京大學 免疫球蛋白
CN121127591A (zh) 2023-05-12 2025-12-12 国立大学法人东京大学 与艰难梭菌结合的抗体
WO2025134928A1 (ja) * 2023-12-21 2025-06-26 国立大学法人 東京大学 結腸直腸がんを治療するための組成物
WO2025220732A1 (ja) * 2024-04-17 2025-10-23 国立研究開発法人国立循環器病研究センター 肺高血圧症の予防又は治療薬
WO2025225737A1 (ja) * 2024-04-26 2025-10-30 国立大学法人 東京大学 微生物と抗体の組み合わせおよび使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003104A1 (en) * 2001-07-02 2003-01-02 John Mottola Method for removal of pathogens from a localized environment
JP5916946B2 (ja) * 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2017001987A (ja) * 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Also Published As

Publication number Publication date
KR20240026999A (ko) 2024-02-29
JP2023123746A (ja) 2023-09-05
EP4365293A4 (en) 2026-03-11
CA3224497A1 (en) 2023-01-05
JPWO2023277142A1 (https=) 2023-01-05
TW202317611A (zh) 2023-05-01
US20250188157A1 (en) 2025-06-12
JP2024041901A (ja) 2024-03-27
JP7405386B2 (ja) 2023-12-26
EP4365293A1 (en) 2024-05-08
JP7425452B2 (ja) 2024-01-31
CN117716035A (zh) 2024-03-15
WO2023277142A1 (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
CN113166256B (zh) 一种新型抗c-kit抗体
CN109790218B (zh) 抗tim-3抗体及其用途
AU2022305377A1 (en) Antibody binding to clostridium difficile
CN112673023B (zh) 抗SIRPα抗体
CN101291954B (zh) 具有改变的细胞信号传导活性的修饰的抗原结合分子
KR101683033B1 (ko) 톨-유사 수용체 3 길항제
KR20260036304A (ko) 항-pd-1/vegfa 이기능성 항체, 이의 약제학적 조성물 및 이의 용도
KR20240026998A (ko) 클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물
CN112457403A (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
KR101758713B1 (ko) 톨-유사 수용체 3 길항제
CN115956087B (zh) 抗-pd-1抗体
CN114366818A (zh) 抗体药物偶联物及其应用
CN114040924B (zh) 对lif具有特异性的结合分子及其用途
KR20140075708A (ko) 대사 및 심혈관 질환의 치료를 위한 톨-유사 수용체 3 길항제
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
KR20230024408A (ko) 항-cldn-18.2 항체 및 그 용도
HK40101827A (zh) 抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途
EA045024B1 (ru) Новое антитело к с-kit
HK1257725A1 (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
HK1257725B (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics